Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis

Published:2021-01 Issue: Volume:Volume 15 Page:253-260
ISSN:1177-5483
Container-title:Clinical Ophthalmology
language:en
Short-container-title:OPTH

Author:

Pessoa Bernardete^ORCID,Malheiro Luísa^ORCID,Carneiro Inês,Monteiro Sílvia^ORCID,Coelho João^ORCID,Coelho Constança^ORCID,Figueira João^ORCID,Meireles Angelina^ORCID,Melo Beirão João Nuno

Publisher

Informa UK Limited

Subject

Ophthalmology

Reference26 articles.

1. Global Prevalence and Major Risk Factors of Diabetic Retinopathy

2. Summary of product characteristics ranibizumab. Approved by EMA. Last updated 2019. 2007.

3. Summary of product characteristics ranibizumab. Approved by FDA revised 2014. 2006.

4. Summary of product characteristics aflibercept. Approved by EMA. Last updated 2019. 2012.

5. Summary of product characteristics bevacizumab. Approved by EMA. Last updated 2018. 2005.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA methyltransferase expression (DNMT1, DNMT3a and DNMT3b) as a potential biomarker for anti-VEGF diabetic macular edema response;European Journal of Ophthalmology;2023-04-20

2. Retrospective analysis of the efficacy of early switching from bevacizumab to aflibercept or ranibizumab in diabetic macular edema;European Journal of Ophthalmology;2022-11-04

3. Monoclonal antibodies in diabetic retinopathy;Expert Review of Clinical Immunology;2022-02-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP